TxCell Granted €1.7M From Bpifrance to Develop Crohn’s Therapy

TxCell Granted €1.7M From Bpifrance to Develop Crohn’s Therapy
Biotechnology company TxCell SA has been granted EUR 1.7 million ($1.9 million) from Bpifrance to support the development of the company’s lead product candidate Ovasave (ovalbumin-specific autologous Treg cells). TxCell is working on the development of novel and cost-effective personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases through the use of antigen specific regulatory T-cells, called

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *